Taxol News and Research

RSS

Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.

Dramatic drop in deaths from most common cancers

The death toll from three of the UK's most common cancers has dropped to its lowest level for almost 40 years* - according to new figures released by Cancer Research UK.

12 Jul 2009

Taxol-carrying nanoparticles

Nanoparticles specially engineered by University of Central Florida Assistant Professor J. Manuel Perez and his colleagues could someday target and destroy tumors, sparing patients from toxic, whole-body chemotherapies.

17 Jun 2009

New research sheds light on ways to improve treatment for aggressive breast cancer

Changing the order that chemotherapy drugs are given to breast cancer patients before surgery makes treatment much more effective, according to trial results presented at the American Society of Clinical Oncology (ASCO) conference, today.

31 May 2009

Researchers target telomeres to attack tumors

Hoping to develop more effective long-term attacks on cancer, researchers at the Indiana University School of Medicine are conducting the first human tests of a breast cancer drug regimen that includes a compound meant to force cancer cells to grow old and die.

5 May 2009

Brain metastases hijack neuron-supporting cells to resist chemotherapy

Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations.

20 Apr 2009

FDA grants Oasmia's Paclical orphan drug designation for ovarian cancer in U.S.

Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical for the treatment of ovarian cancer.

14 Apr 2009

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

neuMirRx issued U.S. patent for "methods for enhancing solubility of compounds

neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled "Methods for Enhancing Solubility of Compounds" which covers novel formulation methods to enhance the solubility of hydrophobic compounds.

15 Oct 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Scientists synthesize promising anti-cancer product from marine algae

Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.

20 Aug 2008

Stanford develop method to overcome multiple drug resistant diseases

Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.

18 Aug 2008

Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.

14 Aug 2008

Researchers show how new chemotherapy drugs kill cancerous tumors

Dr Stephen Taylor and Karen Gascoigne at the University of Manchester's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.

From The University of Manchester 6 Aug 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008

Spectrum Pharmaceuticals to present data on Ortataxel in breast cancer at major oncology meeting

Spectrum Pharmaceuticals, Inc., will present Phase 2 data on ortataxel at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois.

19 May 2008

New key mechanism in cell division discovered

Scientists at the IFOM-IEO Campus have revealed the function of a protein that is indispensable for passing on an accurate copy of the genome from mother to daughter cells. This study, published in Cell, opens up new avenues of research to reduce the toxicity of chemotherapy in the treatment of cancer.

8 May 2008

Wild Mediterranean plant provides potential anticancer medicines

A group of scientists from the Department of Organic Chemistry and the Biotechnology Institute of the University of Granada have found out that the plant “Dittirichia viscose”, known as elecampe, can be used to obtain inhibitors of neurogenic vasodilatation, a significant progress in migraine and cancer treatments.

17 Apr 2008

Mitosis gets harder thanks to new gene discovery

A biological process taught to every pupil studying science at high school has just become a little more complicated thanks to a new discovery published today.

4 Apr 2008

Barr Pharmaceuticals receives approval for generic Taxol injection

Barr Pharmaceuticals, Inc. announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Bristol-Myers Squibb Company's Taxol (paclitaxel) Injection USP, 6mg/mL, packaged in 100mg/16.7 mL and 300mg/50 mL Multiple-dose Vials.

13 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

11 Mar 2008